Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
ATM mutation
Cancer:
Solid Tumor
Drug:
Bavencio (avelumab)
(
PD-L1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Source:
clinicaltrials.gov
Title:
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Excerpt:
Inclusion Criteria: BRCA1, BRCA2 and/or ATM gene defect.
Trial ID:
NCT03565991
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login